Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Response to the SHINGRIX Varicella Zoster Virus (VZV) Vaccine in Chronic Lymphocytic Leukemia (CLL) Patients That Are Treatment Naive or Receiving Bruton s-Tyrosine Kinase Inhibitor (BTK-I) Therapy

Trial Profile

Response to the SHINGRIX Varicella Zoster Virus (VZV) Vaccine in Chronic Lymphocytic Leukemia (CLL) Patients That Are Treatment Naive or Receiving Bruton s-Tyrosine Kinase Inhibitor (BTK-I) Therapy

Recruiting
Phase of Trial: Phase II

Latest Information Update: 11 Mar 2019

At a glance

  • Drugs GSK 1437173A (Primary)
  • Indications Herpes zoster
  • Focus Pharmacodynamics
  • Most Recent Events

    • 07 Dec 2018 Planned initiation date (estimated date of first participant enrolment) changed from 3 Dec 2018 to 13 Dec 2018.
    • 27 Nov 2018 Planned initiation date (estimated date of first participant enrolment) changed from 30 Nov 2018 to 3 Dec 2018.
    • 20 Nov 2018 Planned initiation date (estimated date of first participant enrolment) changed from 1 Nov 2018 to 26 Nov 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top